Foster Family Fixes: Serving Our Most Vulnerable Children with Foster Care Reform

Share on Facebook
Share on Twitter
Share on
LinkedIn
+

Join Joe Selvaggi and Pioneer Senior Healthcare Fellow Josh Archambault as they discuss specific reforms that could improve the current foster care system. Josh shares findings from his recent research, as well as his experiences as a foster parent himself. Read Josh’s recent USA Today op-ed on this topic.

Interview Guest:

Josh Archambault is Pioneer’s Senior Fellow on Health Care Policy. Prior to joining Pioneer, Josh was selected as a Health Policy Fellow at the Heritage Foundation, served as Legislative Director for State Senator Scott Brown, and as a Senior Legislative Aide in the Governor’s Office of Legislative Affairs. Josh holds a Masters in Public Policy from Harvard University’s Kennedy School and a BA in Political Studies and Economics from Gordon College.

Get Our COVID-19 News, Tips & Resources!

  • This field is for validation purposes and should be left unchanged.

Related Research

Pioneer Institute: 340B Hospitals Does Not Necessarily Translate to Charity Care

Review of Becker’s List of Health Systems with Strong Finances…

Average Weekly Wages of Healthcare Workers Across a Decade

From 2012-22 the healthcare and social assistance sector has seen the smallest growth in average weekly wages of any large industry in Massachusetts. This potentially has dire consequences on the employment crisis that this industry already faces.

Do No Harm to the Health Policy Commission

With only weeks left in the Massachusetts legislative calendar,…

New Online Tool Tracks MA Hospital Revenue from Commercial Sources

A new online tool from Pioneer Institute shows a gradual increase in non-commercial (public payer) revenue at Massachusetts hospitals and also reveals a strong relationship between the hospitals with the highest commercial revenue and those with the highest relative prices.

Study Finds Obstacles to Search for Opioid Substitute

Inflation Reduction Act price controls on the category of…

Transformative Medical Therapy Will Require New Cost-Benefit and Pricing Models

Current regulations increase development and manufacturing costs,…

Genetic Therapy Revolution: Benefits and Barriers for Medicine’s New Horizon

Joe Selvaggi talks with neurobiologist and writer Dr. Anne Sydor about the potential for gene therapy to address deadly and debilitating diseases and how current health care models must adapt to encourage this nascent technology.

Boston Children’s, MGH Among Massachusetts Hospitals with Highest Relative Commercial Prices

Pioneer Institute's new tool, the Massachusetts Hospital Relative Price Tracker, displays relative price and facilitates relative price comparisons among hospitals. The average price among all hospitals will have a relative price of 1.0. A relative price of 1.5 means that a hospital charges 50 percent higher than the average of all Massachusetts hospitals. Similarly, a relative price of 0.84 means that a hospital’s prices are 16 percent below average. Relative price data is collected and reported by the Commonwealth’s Center for Health Information and Analysis (CHIA) and is an aggregate measure used to evaluate price variations among different hospitals. It is recalculated annually based on data collected from commercial payers and includes information on private commercial insurance and commercially managed public insurance products such as Medicare Advantage and Medicaid Managed Organizations/Accountable Care Partnership Plans.

Middlemen Pushing Up Retail Costs of Drugs

The reality is that non-price factors, including several players, are causing net prices to decline and retail prices to increase. Those players include employers, health plans, and pharmacy benefit managers (PBMs), all of whom have continuously circumvented the system through loopholes and complicated systems of reimbursement that tend to hurt patients

Telehealth Progress Slowed in 2023

A new report by Cicero Institute, Pioneer Institute, and Reason Foundation reveals worrying stagnation in state-level telehealth expansion efforts in 2023, with only a few exceptions. Progress made during the pandemic is being lost even as provider shortages worsen, raising concerns about patients’ access to care.

‘High’ U.S. Drug Prices Mask Freeloading by Other Nations

The drug company’s choice is to walk away from millions in revenue from a given country and deny their people a lifesaving drug, or swallow hard and accept an unfair price that is nowhere near the drug’s value. For the sake of shareholders and patients, drug companies typically accept the unfair price and devote the revenue to offsetting their previous investments. In short, other nations are freeloading off of American R&D.

Drug Discount Distortions: How Middlemen Increase Costs and Reduce Access

Joe Selvaggi talks with Drs. Bill Smith and Robert Popovian about how the complex system of rebates from drug companies to insurance firms serve to increase costs and reduce access for patients.